Translating microRNAs into biomarkers: What is new for pediatric cancer?

Since their discovery in 2008, cell-free circulating microRNAs have been considered potential biomarkers for various conditions, including pediatric cancer. Diagnosis of pediatric cancer still relies on clinical signs, which sometimes may be non-specific or appear at later stages. Thus, there is a n...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2016-05, Vol.33 (5), p.49-49, Article 49
Main Authors: de Carvalho, Ivna Néria Silva Ribamar, de Freitas, Renata Mendes, Vargas, Fernando Regla
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - blood
Biomarkers, Tumor - genetics
Exosomes - genetics
Gene Expression Profiling - methods
Gene Expression Regulation, Neoplastic
Hematology
Humans
Internal Medicine
Medicine
Medicine & Public Health
MicroRNAs - blood
MicroRNAs - genetics
Neoplasms - genetics
Oncology
Pathology
Review Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since their discovery in 2008, cell-free circulating microRNAs have been considered potential biomarkers for various conditions, including pediatric cancer. Diagnosis of pediatric cancer still relies on clinical signs, which sometimes may be non-specific or appear at later stages. Thus, there is a need for a better understanding of molecules that allow a less invasive, early and effective method of cancer diagnosis. Despite the efforts of many researches to set specific miRNAs to be routinely used as diagnostic molecules, no miR has been currently utilized so far. In this study, we review the recent discoveries on circulating miRNAs in blood of patients suffering from the following pediatric cancers: osteosarcoma, rhabdomyosarcoma, Wilms tumor, acute myeloid leukemia, acute lymphocytic leukemia, retinoblastoma and neuroblastoma. We also focus on the roles of circulating miRs in tumorigenesis pathways, the methodological approaches used to detect and quantify circulating miRs, and discuss the challenges in using them routinely as biomarkers for pediatric cancers.
ISSN:1357-0560
1559-131X
DOI:10.1007/s12032-016-0766-4